Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2067-2026

BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit. Recall

BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.

FDA recall Class II

Ongoing

FDA lists this Class II recall for BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2067-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Apr 22, 2026
FDA report date
May 13, 2026
Quantity in commerce
106 kits (3,180 test)
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.

Affected model & UDI checker

Search the exact identifiers published for Z-2067-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
RFIT-ASY-0138BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.Check source noticeNot specified
FDA code information

Lot #s:0883425,0878825/DI: 00815381020192

View the original FDA recall notice

Why was this product recalled?

Contamination to in-vitro diagnostic test may result in false positives.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Biofire Diagnostics, LLC take?

On April 22, 2026, bioMerieux issued a Urgent Medical Device Recall notification to affected consignees via E-Mail. bioMerieux asked consignees to take the following actions: 1 Examine your inventory for the lots identified in this recall notification. 2 Discontinue use and discard any remaining product from this lot in your possession. 3 Please confirm the quantity of kits that have been destroyed, previously used, or returned on the attached Acknowledgement of Receipt Form. 4 If the product has been transferred to another facility, please notify the facility and appropriate personnel. 5 If you have further distributed this product, please identify any recipients and notify them at once. 6 Please complete the accompanying Acknowledgement of Receipt Form and return to bioMrieux so that bioMrieux may acknowledge your receipt of this notification.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology